DK1392312T3 - Triazolo-4,5 d-pyrimidinderivater og anvendelse deraf som purinerge receptorantagonister - Google Patents
Triazolo-4,5 d-pyrimidinderivater og anvendelse deraf som purinerge receptorantagonisterInfo
- Publication number
- DK1392312T3 DK1392312T3 DK02729452T DK02729452T DK1392312T3 DK 1392312 T3 DK1392312 T3 DK 1392312T3 DK 02729452 T DK02729452 T DK 02729452T DK 02729452 T DK02729452 T DK 02729452T DK 1392312 T3 DK1392312 T3 DK 1392312T3
- Authority
- DK
- Denmark
- Prior art keywords
- alkyl
- aryl
- disorder
- formula
- receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0100624.6A GB0100624D0 (en) | 2001-01-10 | 2001-01-10 | Chemical compounds VII |
PCT/GB2002/000091 WO2002055083A1 (en) | 2001-01-10 | 2002-01-10 | TRIAZOLO[4,5-d] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1392312T3 true DK1392312T3 (da) | 2009-06-15 |
Family
ID=9906571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02729452T DK1392312T3 (da) | 2001-01-10 | 2002-01-10 | Triazolo-4,5 d-pyrimidinderivater og anvendelse deraf som purinerge receptorantagonister |
Country Status (27)
Country | Link |
---|---|
US (3) | US7141575B2 (da) |
EP (1) | EP1392312B1 (da) |
JP (2) | JP4287146B2 (da) |
KR (1) | KR100913845B1 (da) |
CN (3) | CN101691370A (da) |
AT (1) | ATE424207T1 (da) |
AU (1) | AU2002219355B2 (da) |
BR (1) | BR0206559A (da) |
CA (1) | CA2433453C (da) |
CZ (1) | CZ301916B6 (da) |
DE (1) | DE60231394D1 (da) |
DK (1) | DK1392312T3 (da) |
ES (1) | ES2323301T3 (da) |
GB (1) | GB0100624D0 (da) |
HK (1) | HK1061206A1 (da) |
HR (1) | HRP20030533A2 (da) |
HU (1) | HUP0401047A3 (da) |
IL (2) | IL156713A0 (da) |
MX (1) | MXPA03006165A (da) |
NO (1) | NO328475B1 (da) |
NZ (1) | NZ527248A (da) |
PL (1) | PL363101A1 (da) |
PT (1) | PT1392312E (da) |
RS (1) | RS51121B (da) |
RU (1) | RU2317084C2 (da) |
WO (1) | WO2002055083A1 (da) |
ZA (1) | ZA200305087B (da) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2842424A1 (fr) * | 2002-07-22 | 2004-01-23 | Univ Paris 7 Denis Diderot | Utilisation du nad ou de l'un de ses analogues, substrat des mono-adp-ribosyl tranferases, pour la preparation d'un medicament destine au traitement des pathologies liees aux recepteurs purinergiques |
NZ540493A (en) * | 2002-12-19 | 2008-04-30 | Schering Corp | Uses of adenosine A2a receptor antagonists |
MXPA05011366A (es) | 2003-04-23 | 2005-11-28 | Schering Corp | Antagonistas del receptor a2a de 2-alquinil- y 2-alquenil-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidina adenosina. |
US7138401B2 (en) * | 2003-09-18 | 2006-11-21 | Conforma Therapeutics Corporation | 2-aminopurine analogs having HSP90-inhibiting activity |
TW200538118A (en) | 2004-04-21 | 2005-12-01 | Schering Corp | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists |
CA2581105A1 (en) | 2004-09-22 | 2006-03-30 | H. Lundbeck A/S | 2-acylaminothiazole derivatives |
CN100398542C (zh) * | 2005-03-18 | 2008-07-02 | 北京大学 | 具有抗hiv活性的取代1,2,3-三唑并嘧啶新化合物,制备方法及用途 |
NZ561939A (en) * | 2005-03-30 | 2011-03-31 | Conforma Therapeutics Corp | Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors |
US7674912B2 (en) | 2005-04-25 | 2010-03-09 | H. Lundbeck A/S | Pro-drugs of N-thiazol-2-yl-benzamide derivatives |
EP2258372B8 (en) * | 2005-06-07 | 2012-12-19 | Kyowa Hakko Kirin Co., Ltd. | A2A antagonists for use in the treatment of motor disorders |
EP1921077B1 (en) * | 2005-08-02 | 2017-07-26 | Kyowa Hakko Kirin Co., Ltd. | Agent for treating and/or preventing sleep disorder |
ATE538123T1 (de) | 2005-09-19 | 2012-01-15 | Schering Corp | 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors |
AR056080A1 (es) | 2005-09-23 | 2007-09-19 | Schering Corp | 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine |
WO2007035963A2 (en) * | 2005-09-23 | 2007-03-29 | Conforma Therapeutics Corporation | Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors |
DE102005049954A1 (de) * | 2005-10-19 | 2007-05-31 | Sanofi-Aventis Deutschland Gmbh | Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen |
WO2007149211A1 (en) * | 2006-06-22 | 2007-12-27 | Board Of Regents, University Of Texas System | Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity |
EP2117308A1 (en) * | 2007-01-05 | 2009-11-18 | Biogen Idec MA Inc. | Polymorphs and solvates of a pharmaceutical and methods of making |
AU2008206591A1 (en) * | 2007-01-12 | 2008-07-24 | Biogen Idec Ma Inc. | Pharmaceuticals, compositions and methods of making and using the same |
FR2915198B1 (fr) * | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
FR2915197B1 (fr) * | 2007-04-18 | 2009-06-12 | Sanofi Aventis Sa | Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique. |
FR2915199B1 (fr) | 2007-04-18 | 2010-01-22 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique. |
AU2009222047A1 (en) | 2008-03-04 | 2009-09-11 | Schering Corporation | 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine A2a receptor antagonists |
AU2009222040A1 (en) * | 2008-03-04 | 2009-09-11 | Schering Corporation | Amino-quinoxaline and amino-quinoline compounds for use as adenosine A2a receptor antagonists |
TWI473614B (zh) * | 2008-05-29 | 2015-02-21 | Kyowa Hakko Kirin Co Ltd | Anti-analgesic inhibitors |
US9622669B2 (en) * | 2008-06-13 | 2017-04-18 | Parkinson's Institute | Diagnosis of neurodegenerative disorders |
GB0906579D0 (en) | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
WO2010010908A1 (ja) * | 2008-07-23 | 2010-01-28 | 協和発酵キリン株式会社 | 片頭痛治療剤 |
CN105399731A (zh) * | 2008-12-24 | 2016-03-16 | 比亚尔-珀特拉和Ca股份公司 | 药物化合物 |
CN102438624B (zh) | 2009-03-13 | 2016-03-30 | 阿德维纳斯治疗私人有限公司 | 取代的稠合嘧啶化合物 |
WO2011050160A1 (en) * | 2009-10-22 | 2011-04-28 | Biogen Idec Ma Inc. | Pharmaceuticals, compositions and methods of making and using the same |
US8796290B2 (en) | 2009-11-09 | 2014-08-05 | Advinus Therapeutics Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
WO2011060207A1 (en) | 2009-11-16 | 2011-05-19 | Schering Corporation | FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY |
DK2531492T3 (da) | 2010-02-05 | 2016-07-04 | Heptares Therapeutics Ltd | 1,2,4-triazin-4-aminderivater |
WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
WO2014101120A1 (en) * | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
US10138212B2 (en) | 2015-02-06 | 2018-11-27 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as A2A antagonist |
AU2016379425B2 (en) | 2015-12-24 | 2021-11-11 | Corvus Pharmaceuticals, Inc. | Methods of treating cancer |
CN107021963A (zh) * | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
AU2017368332A1 (en) | 2016-12-03 | 2019-06-13 | Juno Therapeutics, Inc. | Methods for modulation of CAR-T cells |
JP7227131B2 (ja) | 2016-12-03 | 2023-02-21 | ジュノー セラピューティクス インコーポレイテッド | Car-t細胞の投薬を決定するための方法 |
CN106883191A (zh) * | 2017-01-19 | 2017-06-23 | 华侨大学 | 一种n‑取代苯并三氮唑衍生物的制备方法 |
US11066413B2 (en) * | 2017-03-07 | 2021-07-20 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof |
EP3600292A4 (en) * | 2017-03-30 | 2021-04-07 | Corvus Pharmaceuticals, Inc. | PROCESS FOR THE MANUFACTURING OF TRIAZOLE [4,5D] PYRAMIDINE DERIVATIVES AND INTERMEDIATES THEREOF |
US11040040B2 (en) | 2017-04-04 | 2021-06-22 | Corvus Pharmaceuticals, Inc. | Methods of treating cancer |
AU2018250336A1 (en) | 2017-04-07 | 2019-09-26 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods |
KR20200054160A (ko) | 2017-06-02 | 2020-05-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법 |
US20220225597A1 (en) | 2017-06-29 | 2022-07-21 | Juno Therapeutics, Inc. | Mouse model for assessing toxicities associated with immunotherapies |
AU2018360800A1 (en) | 2017-11-01 | 2020-05-14 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen (BCMA) |
WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
US11623961B2 (en) | 2017-11-01 | 2023-04-11 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for B-cell maturation antigen |
US20210198372A1 (en) | 2017-12-01 | 2021-07-01 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
JP2021506260A (ja) | 2017-12-15 | 2021-02-22 | ジュノー セラピューティクス インコーポレイテッド | 抗cct5結合分子およびその使用方法 |
WO2019123482A1 (en) | 2017-12-19 | 2019-06-27 | Impetis Biosciences Ltd. | Pharmaceutical composition for the treatment of cancer |
KR20200106176A (ko) | 2018-01-04 | 2020-09-11 | 임페티스 바이오사이언시즈 엘티디. | 삼환식 화합물, 삼환식 화합물을 포함하는 조성물 및 이의 의약적 용도 |
EP3814357B1 (en) * | 2018-06-27 | 2024-05-01 | PTC Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating huntington's disease |
WO2020068583A1 (en) * | 2018-09-27 | 2020-04-02 | Corvus Pharmaceuticals, Inc. | Processes for making triazolo [4,5d] pyramidine derivatives and intermediates thereof |
CA3117419A1 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
US20210393689A1 (en) | 2018-11-01 | 2021-12-23 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
BR112021009420A2 (pt) | 2018-11-16 | 2021-11-23 | Juno Therapeutics Inc | Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b |
EP3886875B1 (en) | 2018-11-30 | 2024-05-08 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
PE20212198A1 (es) | 2019-01-29 | 2021-11-16 | Juno Therapeutics Inc | Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1) |
CN110251518A (zh) * | 2019-06-28 | 2019-09-20 | 青岛科技大学 | 1,2,4-三氮唑类杂环化合物在制备预防或治疗与中枢系统相关疾病药物中的应用 |
CN112592354B (zh) | 2019-07-30 | 2022-05-27 | 厦门宝太生物科技股份有限公司 | 一种异噁唑并嘧啶类杂环化合物的制备方法 |
CN112574214B (zh) | 2019-07-30 | 2021-09-28 | 杭州阿诺生物医药科技有限公司 | 腺苷受体拮抗剂的制备方法 |
WO2021050688A1 (en) * | 2019-09-10 | 2021-03-18 | X-Chem, Inc. | Compounds and uses thereof |
CN114667282A (zh) * | 2019-10-22 | 2022-06-24 | 昊运股份有限公司 | 嘧啶酰胺化合物及治疗癌症的方法 |
CA3179800A1 (en) | 2020-04-10 | 2021-10-14 | Juno Therapeutics, Inc. | Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen |
CN111333655B (zh) * | 2020-04-13 | 2021-07-13 | 武汉工程大学 | 一种三唑并嘧啶类化合物及其制备方法和应用 |
WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
US20240041929A1 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56131587A (en) | 1980-03-18 | 1981-10-15 | Ss Pharmaceut Co Ltd | 7-substituted triazolopyrimidine derivative and its preparation |
JPS56131586A (en) | 1980-03-18 | 1981-10-15 | Ss Pharmaceut Co Ltd | Triazolopyrimidine derivative and its preparation |
JPS5962595A (ja) | 1982-09-30 | 1984-04-10 | Ss Pharmaceut Co Ltd | 3,5,7―トリ置換―トリアゾロピリミジン誘導体 |
DE3304330A1 (de) | 1983-02-09 | 1984-08-09 | Basf Ag, 6700 Ludwigshafen | Neue 2h-v-triazolyl(4,5-d)-pyrimidine und deren verwendung |
JPS60140335A (ja) | 1983-12-28 | 1985-07-25 | Konishiroku Photo Ind Co Ltd | 熱現像カラ−感光材料 |
US5204353A (en) | 1987-04-07 | 1993-04-20 | Ciba-Geigy Corporation | 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith |
US5194581A (en) | 1989-03-09 | 1993-03-16 | Leong Kam W | Biodegradable poly(phosphoesters) |
KR960704855A (ko) | 1993-10-12 | 1996-10-09 | 돈 엠. 커. | 1n-알킬-n-아릴피리미딘아민 및 이들의 유도체 (1n-alkyl-n-arylpyrimidinamines and derivatives thereof) |
BR9609467A (pt) | 1995-07-11 | 1999-03-02 | Astra Pharma Prod | Composto uso de um composto composição farmacéutica e processos para preparação de um composto e tratamento de distúrbios de agregação planquetária |
ZA971896B (en) * | 1996-03-26 | 1998-09-07 | Du Pont Merck Pharma | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives |
EA002769B1 (ru) * | 1996-08-28 | 2002-08-29 | Пфайзер Инк. | Замещенные 6,5-гетеробициклические производные |
AU743910B2 (en) * | 1997-03-24 | 2002-02-07 | Kyowa Hakko Kirin Co., Ltd. | {1,2,4}triazolo{1,5-c}pyrimidine derivatives |
US5912225A (en) * | 1997-04-14 | 1999-06-15 | Johns Hopkins Univ. School Of Medicine | Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same |
CA2288014A1 (en) * | 1997-04-30 | 1998-11-05 | Guilford Pharmaceuticals Inc. | Biodegradable compositions comprising poly(cycloaliphatic phosphoester) compounds, articles, and methods for using the same |
US6028163A (en) | 1997-06-27 | 2000-02-22 | Guilford Pharmaceuticals Inc. | Solution polymerization of high molecular weight poly(phosphoesters) in toluene |
EP0994860A1 (en) | 1997-07-03 | 2000-04-26 | Du Pont Pharmaceuticals Company | Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists |
US5939432A (en) | 1997-10-29 | 1999-08-17 | Medco Research, Inc. | Thiophenes useful for modulating the adenosine receptor |
US6197788B1 (en) | 1997-11-26 | 2001-03-06 | Vernalis Research Limited | (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders |
WO1999035147A1 (fr) | 1998-01-05 | 1999-07-15 | Eisai Co., Ltd. | Derives de purine et antagonistes du recepteur a2 d'adenosine utiles comme moyens de prevention/traitement du diabete |
GB9819384D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
GB9819382D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
GB9915437D0 (en) | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
US6841549B1 (en) | 1999-07-02 | 2005-01-11 | Eisai Co., Ltd. | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
-
2001
- 2001-01-10 GB GBGB0100624.6A patent/GB0100624D0/en not_active Ceased
-
2002
- 2002-01-10 KR KR1020037009240A patent/KR100913845B1/ko not_active IP Right Cessation
- 2002-01-10 IL IL15671302A patent/IL156713A0/xx unknown
- 2002-01-10 AU AU2002219355A patent/AU2002219355B2/en not_active Ceased
- 2002-01-10 HU HU0401047A patent/HUP0401047A3/hu unknown
- 2002-01-10 US US10/250,942 patent/US7141575B2/en not_active Expired - Lifetime
- 2002-01-10 BR BR0206559-2A patent/BR0206559A/pt not_active Application Discontinuation
- 2002-01-10 JP JP2002555817A patent/JP4287146B2/ja not_active Expired - Lifetime
- 2002-01-10 PL PL02363101A patent/PL363101A1/xx not_active Application Discontinuation
- 2002-01-10 DK DK02729452T patent/DK1392312T3/da active
- 2002-01-10 NZ NZ527248A patent/NZ527248A/en active IP Right Revival
- 2002-01-10 AT AT02729452T patent/ATE424207T1/de active
- 2002-01-10 ZA ZA200305087A patent/ZA200305087B/xx unknown
- 2002-01-10 EP EP02729452A patent/EP1392312B1/en not_active Expired - Lifetime
- 2002-01-10 CZ CZ20031955A patent/CZ301916B6/cs not_active IP Right Cessation
- 2002-01-10 CA CA2433453A patent/CA2433453C/en not_active Expired - Lifetime
- 2002-01-10 ES ES02729452T patent/ES2323301T3/es not_active Expired - Lifetime
- 2002-01-10 RU RU2003124651/04A patent/RU2317084C2/ru not_active IP Right Cessation
- 2002-01-10 WO PCT/GB2002/000091 patent/WO2002055083A1/en active IP Right Grant
- 2002-01-10 CN CN200910164664A patent/CN101691370A/zh active Pending
- 2002-01-10 CN CNA2008100024015A patent/CN101214248A/zh active Pending
- 2002-01-10 CN CNA028063031A patent/CN1496262A/zh active Pending
- 2002-01-10 MX MXPA03006165A patent/MXPA03006165A/es active IP Right Grant
- 2002-01-10 RS YUP-555/03A patent/RS51121B/sr unknown
- 2002-01-10 PT PT02729452T patent/PT1392312E/pt unknown
- 2002-01-10 DE DE60231394T patent/DE60231394D1/de not_active Expired - Lifetime
-
2003
- 2003-06-30 IL IL156713A patent/IL156713A/en not_active IP Right Cessation
- 2003-06-30 HR HR20030533A patent/HRP20030533A2/hr not_active Application Discontinuation
- 2003-07-09 NO NO20033146A patent/NO328475B1/no not_active IP Right Cessation
-
2004
- 2004-06-15 HK HK04104319.2A patent/HK1061206A1/xx not_active IP Right Cessation
-
2006
- 2006-08-22 US US11/507,625 patent/US7405219B2/en not_active Expired - Lifetime
-
2007
- 2007-12-20 US US12/003,110 patent/US7589097B2/en not_active Expired - Lifetime
-
2008
- 2008-12-02 JP JP2008308004A patent/JP5202259B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1392312T3 (da) | Triazolo-4,5 d-pyrimidinderivater og anvendelse deraf som purinerge receptorantagonister | |
DE60228414D1 (de) | Pyrrolo 2,3-d pyrimidine und deren verwendung als purinreceptor antagonisten | |
YU55603A (sh) | Derivati purina kao antagonisti purinergiskog receptora | |
DE60228817D1 (de) | THIENO(3,2-d)PYRIMIDINE UND FURANO(3,2-d)PYRIMIDINE UND DEREN VERWENDUNG ALS ANTAGONISTEN AN PURINERGEN REZEPTOREN | |
PE20010430A1 (es) | DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a | |
PE20020104A1 (es) | Derivados de benzotiazol | |
PE20040893A1 (es) | DERIVADOS DE INDOL O DERIVADOS DE BENCIMIDAZOL PARA MODULAR IkB QUINASA | |
HK1068334A1 (en) | Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments | |
PE20000270A1 (es) | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol | |
PE20091268A1 (es) | Derivados heterociclicos como inhibidores de pi3 quinasa | |
HUP0102300A2 (hu) | Diazepinszármazékok alkalmazása szomatosztatin-receptor által befolyásolt betegségek kezelésére szánt gyógyszerek előállítására, valamint új vegyületek | |
NO20025651D0 (no) | Adenosin A2A-reseptorantagonister | |
CY1109263T1 (el) | Ανταγωνιστες των α2α υποδοχεων αδενοσινης 2-alkynyl-kai 2-αλκενυλ-pyrazolo-[4,3-ε]-1,2,4-triazolo-[1,5-c]-pyrimidine | |
ATE307132T1 (de) | Purin derivate als a2b adenosin rezeptor antagonisten | |
DK1107973T3 (da) | Hidtil ukendte thieno(2,3-D)pyrimidindioner, fremgangsmåde til deres fremstilling og anvendelse deraf i terapi | |
ATE238334T1 (de) | Nucleosid-derivate mit photolabilen schutzgruppen |